Australia's Cyclopharm rises on med-tech clinical guideline win in US

Shares of Cyclopharm CYC.AX advance as much as 15.34% to A$1.015, their biggest intraday pct gain December 1, 2025

The radiopharmaceutical co notes a key draft U.S. clinical guideline from the country's peak nuclear medicine body, which explicitly names its Technegas lung‑imaging agent as a preferred ventilation option

Separately, co says its insurer has accepted indemnity over legal proceedings lodged by med tech co 4DMedical 4DX.AX and has assumed conduct of the defence on the firm's behalf

Proceedings alleged that CYC made false or misleading comments during a webinar in March last year about 4DX's capital‑raising statements

Over 66,000 shares change hands, 2.3x the 30-day avg

Stock last year lost 38.2%